Streetbeat News

Stock Prices

GMS

GMS Inc. reported Q2 earnings of $2.30 per share, surpassing the consensus estimate of $2.26, and sales of $1.42B, also beating the estimate of $1.38B. However, these figures represent a decrease from the previous year, with earnings down 17.56% and sales down 0.70%.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:01 am

GENE

Genetic Technologies announced that NASDAQ confirmed the first trading date of its consolidated American Depositary Shares (ADS) will be December 14.

Portfolio Pulse from Charles Gross

December 07, 2023 | 10:59 am

FEAM

B. Riley Securities analyst Matthew Key has downgraded 5E Advanced Materials (FEAM) from Buy to Neutral and reduced the price target from $4 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:52 am

TSLA

Gordon Johnson, CEO of GLJ Research and a known Tesla bear, has accused the NHTSA of being 'bought and paid for' due to a lack of action on complaints about Tesla's Model 3 and Model Y phantom braking issues. The complaints increased after Tesla disabled radar in these models in May 2021. Despite Johnson's accusations, the NHTSA did start a review of customer complaints in February 2022.

Portfolio Pulse from Anan Ashraf

December 07, 2023 | 10:50 am

CERE

Cantor Fitzgerald analyst Charles Duncan has downgraded Cerevel Therapeutics Holdings (CERE) from Overweight to Neutral, while increasing the price target from $38 to $45.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:50 am

DHR

Goldman Sachs analyst Matthew Sykes has downgraded Danaher (NYSE:DHR) from Buy to Neutral and reduced the price target from $215 to $205.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:49 am

CXM

Sprinklr Inc (NYSE:CXM) shares plummeted over 20% despite reporting Q3 FY24 results that exceeded consensus estimates. Revenue increased by 18% Y/Y to $186.3 million, surpassing the expected $180.4 million. Subscription revenue grew by 22% Y/Y, and both RPO and cRPO saw significant year-over-year increases. Non-GAAP operating income and adjusted EPS also beat expectations. The company raised its FY24 revenue and EPS guidance. However, shares dropped to $13.10 in premarket trading.

Portfolio Pulse from Lekha Gupta

December 07, 2023 | 10:47 am

SNDR

Wells Fargo analyst Allison Poliniak Cusic upgraded Schneider National (NYSE:SNDR) from Underweight to Equal-Weight and increased the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:45 am

VTGN

Jefferies analyst Andrew Tsai has upgraded Vistagen Therapeutics (NASDAQ: VTGN) from Hold to Buy and significantly increased the price target from $0.2 to $15.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:35 am

BVS

Canaccord Genuity analyst William Plovanic upgraded Bioventus (NASDAQ:BVS) from Hold to Buy and increased the price target from $3.66 to $7, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 10:31 am